Transarterial Radioembolization versus Transarterial Chemoembolization Plus Percutaneous Ablation for Unresectable, Solitary Hepatocellular Carcinoma of ≥3 cm: A Propensity Score–Matched Study

医学 肝细胞癌 倾向得分匹配 烧蚀 危险系数 经皮 微波消融 总体生存率 核医学 外科 内科学 泌尿科
作者
Qian Yu,Nihal Thapa,Kunal B. Karani,Rakesh Navuluri,Osman S. Ahmed,Thuong Van Ha
出处
期刊:Journal of Vascular and Interventional Radiology [Elsevier BV]
卷期号:33 (12): 1570-1577.e1 被引量:9
标识
DOI:10.1016/j.jvir.2022.09.005
摘要

Abstract

Purpose

To compare safety and effectiveness of transarterial radioembolization (TARE) and transarterial chemoembolization (TACE) with drug-eluting embolic agents combined with percutaneous ablation (TACE+ablation) in treatment of treatment-naïve, unresectable, solitary hepatocellular carcinoma (HCC) ≥3cm.

Methods

29 patients with treatment-naïve solitary unresectable HCC ≥3cm received a combined TACE+ablation and 40 patients received TARE at a single institution. Local tumor response, tumor progression-free survival, overall survival, need for re-intervention, bridge to transplant, and major complications were compared. Clinical variables and outcomes were compared before and after propensity score matching (PSM).

Results

Before PSM, patients who underwent TARE had larger tumor size (3.7 vs 5.5 cm, p=0.0005) and older age (61.5 vs 69.3 years, p=0.0014). After PSM, there was no difference in baseline characteristics between two groups with mean tumor size measuring 3.9 cm in TACE+ablation and 4.1 cm in TARE (p=0.90) cohorts. After PSM (n=19 in each group), no statistically significant difference was observed in local radiological response (disease control rates 100% vs 94.7%, p=0.31), survival (SHR [subdistribution hazard ratio] 0.71, 95% CI [0.28-1.80], p=0.469), progression-free survival (SHR 0.61, 95%CI [0.21-1.71], p=0.342), bridge to transplant (21.1% vs 31.6%, p=0.46), and major complication rates (15.8% vs 10.5%, p=0.63) between the two groups. The mean total number of locoregional intervention was higher in the TACE+Ablation cohort (1.9 vs 1.3 sessions, p=0.02) with an earlier median re-intervention trend (SHR 0.61, 95%CI [0.20-1.32], p=0.167).

Conclusions

The present study showed that TARE and the combination of TACE and ablation are comparable in safety and effectiveness for treating unresectable, treatment-naïve, solitary HCC ≥ 3 cm.

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
LMBxXw完成签到,获得积分10
1秒前
呆瓜不呆发布了新的文献求助10
1秒前
大男发布了新的文献求助10
2秒前
3秒前
3秒前
3秒前
多情天荷完成签到,获得积分10
4秒前
JamesPei的应助被lykkk采纳,获得10
4秒前
kkaky完成签到,获得积分10
4秒前
4秒前
DYAZZYYZ完成签到,获得积分10
4秒前
Lily发布了新的文献求助30
5秒前
研友_滕谷完成签到,获得积分10
5秒前
SciGPT的应助被超浓抹茶椰采纳,获得10
6秒前
7秒前
xzh完成签到,获得积分20
7秒前
warden完成签到 ,获得积分10
7秒前
9秒前
荣离枯发布了新的文献求助10
9秒前
月儿发布了新的文献求助10
9秒前
烟花的应助被呆瓜不呆采纳,获得10
10秒前
汉堡包的应助被大男采纳,获得10
10秒前
秒速五厘米的应助被山海不远采纳,获得10
11秒前
极限001的应助被荼蘼采纳,获得30
11秒前
慕青的应助被荼蘼采纳,获得10
12秒前
科研通AI6.4的应助被荼蘼采纳,获得10
12秒前
12秒前
科研通AI6.3的应助被荼蘼采纳,获得10
12秒前
Abracadabra的应助被荼蘼采纳,获得10
12秒前
NexusExplorer的应助被荼蘼采纳,获得30
12秒前
科研通AI6.3的应助被荼蘼采纳,获得10
12秒前
科研通AI6.4的应助被荼蘼采纳,获得10
12秒前
科研通AI6.4的应助被荼蘼采纳,获得10
12秒前
极限001的应助被荼蘼采纳,获得30
12秒前
林荫街皮蛋瘦肉株完成签到,获得积分10
13秒前
葱姜蒜Moi完成签到,获得积分10
13秒前
flamez发布了新的文献求助10
13秒前
铁骨完成签到,获得积分10
14秒前
15秒前
昭仪完成签到 ,获得积分10
15秒前
高分求助中
(应助此贴封号)【重要!!请各用户(尤其是新用户)详细阅读】【科研通的精品贴汇总】 10000
拉伸高分子熔体中缠结行为的模拟和小角中子散射研究 1700
奈特基础组织学:配套组织病理学(第4版)(Netter's Essential Histology With Correlated Histopathology) 800
John McDowells Bildungstheorie 800
八旗制度の研究 600
plantTFDB 508
Resource Recovery Handbook 500
热门求助领域 (近24小时)
化学 材料科学 医学 生物 纳米技术 计算机科学 工程类 有机化学 化学工程 生物化学 物理 复合材料 内科学 催化作用 光电子学 人工智能 细胞生物学 无机化学 物理化学 数学
热门帖子
关注 科研通微信公众号,转发送积分 8175305
求助须知:如何正确求助?哪些是违规求助? 9567097
关于积分的说明 21790117
捐赠科研通 7769782
什么是DOI,文献DOI怎么找? 3431840
关于科研通互助平台的介绍 2556149
邀请新用户注册赠送积分活动 2477241